CN109311888B - 哌啶基衍生物,其制备方法和含有它们的药物组合物 - Google Patents

哌啶基衍生物,其制备方法和含有它们的药物组合物 Download PDF

Info

Publication number
CN109311888B
CN109311888B CN201780035584.8A CN201780035584A CN109311888B CN 109311888 B CN109311888 B CN 109311888B CN 201780035584 A CN201780035584 A CN 201780035584A CN 109311888 B CN109311888 B CN 109311888B
Authority
CN
China
Prior art keywords
methyl
pyrimidin
pyrrolo
carbonyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780035584.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109311888A (zh
Inventor
A·科斯基
C·韦伯
A·华沙斯
B·莫尔纳
A·基斯
A·玛西亚斯
J·B·穆雷
E·刘可维茨
O·热内斯特
M·尚里翁
D·德马勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Original Assignee
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Furnalis R&d Co ltd, Les Laboratoires Servier SAS filed Critical Furnalis R&d Co ltd
Publication of CN109311888A publication Critical patent/CN109311888A/zh
Application granted granted Critical
Publication of CN109311888B publication Critical patent/CN109311888B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201780035584.8A 2016-06-10 2017-06-09 哌啶基衍生物,其制备方法和含有它们的药物组合物 Expired - Fee Related CN109311888B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1655392 2016-06-10
FR1655392A FR3052452B1 (fr) 2016-06-10 2016-06-10 Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2017/064067 WO2017212012A1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
CN109311888A CN109311888A (zh) 2019-02-05
CN109311888B true CN109311888B (zh) 2021-09-14

Family

ID=56943687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780035584.8A Expired - Fee Related CN109311888B (zh) 2016-06-10 2017-06-09 哌啶基衍生物,其制备方法和含有它们的药物组合物

Country Status (46)

Country Link
US (1) US11046681B2 (cg-RX-API-DMAC10.html)
EP (1) EP3468974B1 (cg-RX-API-DMAC10.html)
JP (1) JP6928005B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190016106A (cg-RX-API-DMAC10.html)
CN (1) CN109311888B (cg-RX-API-DMAC10.html)
AR (1) AR108706A1 (cg-RX-API-DMAC10.html)
AU (1) AU2017277734B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018075433A2 (cg-RX-API-DMAC10.html)
CA (1) CA3027014C (cg-RX-API-DMAC10.html)
CL (1) CL2018003474A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018013210A2 (cg-RX-API-DMAC10.html)
CR (1) CR20180564A (cg-RX-API-DMAC10.html)
CU (1) CU20180145A7 (cg-RX-API-DMAC10.html)
CY (1) CY1122870T1 (cg-RX-API-DMAC10.html)
DK (1) DK3468974T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2018000270A (cg-RX-API-DMAC10.html)
EA (1) EA037211B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP18090144A (cg-RX-API-DMAC10.html)
ES (1) ES2775789T3 (cg-RX-API-DMAC10.html)
FR (1) FR3052452B1 (cg-RX-API-DMAC10.html)
GE (2) GEP20207160B (cg-RX-API-DMAC10.html)
HR (1) HRP20200361T1 (cg-RX-API-DMAC10.html)
HU (1) HUE049507T2 (cg-RX-API-DMAC10.html)
IL (1) IL263463B (cg-RX-API-DMAC10.html)
LT (1) LT3468974T (cg-RX-API-DMAC10.html)
MA (1) MA45222B1 (cg-RX-API-DMAC10.html)
MD (1) MD3468974T2 (cg-RX-API-DMAC10.html)
ME (1) ME03670B (cg-RX-API-DMAC10.html)
MX (1) MX374794B (cg-RX-API-DMAC10.html)
MY (1) MY196562A (cg-RX-API-DMAC10.html)
NI (1) NI201800132A (cg-RX-API-DMAC10.html)
NZ (1) NZ748946A (cg-RX-API-DMAC10.html)
PE (1) PE20220567A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018502515B1 (cg-RX-API-DMAC10.html)
PL (1) PL3468974T3 (cg-RX-API-DMAC10.html)
PT (1) PT3468974T (cg-RX-API-DMAC10.html)
RS (1) RS60029B1 (cg-RX-API-DMAC10.html)
RU (1) RU2743163C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201810629QA (cg-RX-API-DMAC10.html)
SI (1) SI3468974T1 (cg-RX-API-DMAC10.html)
SV (1) SV2018005791A (cg-RX-API-DMAC10.html)
TN (1) TN2018000410A1 (cg-RX-API-DMAC10.html)
TW (1) TWI620750B (cg-RX-API-DMAC10.html)
UA (1) UA123794C2 (cg-RX-API-DMAC10.html)
UY (1) UY37288A (cg-RX-API-DMAC10.html)
WO (1) WO2017212012A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
TW201925202A (zh) * 2017-11-29 2019-07-01 法商施維雅藥廠 新穎哌啶基衍生物、其製備方法及含其之醫藥組合物
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
TW202024093A (zh) 2018-09-21 2020-07-01 美商安塔製藥公司 作為抗病毒劑之官能化雜環
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
US20220033397A1 (en) * 2018-12-06 2022-02-03 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075555A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
PL3468971T3 (pl) * 2016-06-10 2020-08-10 Les Laboratoires Servier Nowe pochodne (hetero)arylo-piperydynylowe, sposoby ich wytwarzania oraz zawierające je kompozycje

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075555A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Whole Cell Target Engagement Identifies Novel Inhibitors of Mycobacterium tuberculosis Decaprenylphosphoryl-β‑D‑ribose Oxidase;Sarah M. Batt et al.;《ACS Infect. Dis.》;20150813;第1卷;第615-626页 *
基于高通量测序的海滨雀稗转录组学研究;贾新平 等;《草业学报》;20141231;第23卷(第6期);第242-252页 *

Also Published As

Publication number Publication date
FR3052452A1 (cg-RX-API-DMAC10.html) 2017-12-15
LT3468974T (lt) 2020-04-10
RS60029B1 (sr) 2020-04-30
JP2019517556A (ja) 2019-06-24
PL3468974T3 (pl) 2020-07-13
EA201892838A1 (ru) 2019-06-28
CA3027014C (en) 2021-01-05
ECSP18090144A (es) 2019-01-31
SV2018005791A (es) 2019-01-16
CO2018013210A2 (es) 2018-12-28
DK3468974T3 (da) 2020-05-11
UY37288A (es) 2018-01-02
EP3468974A1 (en) 2019-04-17
PE20220567A1 (es) 2022-04-13
GEAP202014978A (en) 2020-06-10
ES2775789T3 (es) 2020-07-28
PH12018502515B1 (en) 2021-11-10
MX2018015216A (es) 2019-04-25
CN109311888A (zh) 2019-02-05
AR108706A1 (es) 2018-09-19
MD3468974T2 (ro) 2020-05-31
JP6928005B2 (ja) 2021-09-01
HUE049507T2 (hu) 2020-09-28
CY1122870T1 (el) 2021-05-05
MY196562A (en) 2023-04-19
WO2017212012A1 (en) 2017-12-14
BR112018075433A2 (pt) 2019-03-19
MA45222A (fr) 2019-04-17
EP3468974B1 (en) 2020-02-12
TW201802092A (zh) 2018-01-16
TN2018000410A1 (en) 2020-06-15
AU2017277734A1 (en) 2018-12-20
DOP2018000270A (es) 2019-05-15
RU2018147430A3 (cg-RX-API-DMAC10.html) 2020-07-10
NI201800132A (es) 2019-04-08
UA123794C2 (uk) 2021-06-02
TWI620750B (zh) 2018-04-11
IL263463B (en) 2021-01-31
EA037211B1 (ru) 2021-02-19
SI3468974T1 (sl) 2020-07-31
CU20180145A7 (es) 2019-07-04
SG11201810629QA (en) 2018-12-28
MA45222B1 (fr) 2020-04-30
US20190144448A1 (en) 2019-05-16
PT3468974T (pt) 2020-03-25
NZ748946A (en) 2025-06-27
ME03670B (en) 2020-10-20
AU2017277734B2 (en) 2021-07-01
US11046681B2 (en) 2021-06-29
RU2018147430A (ru) 2020-07-10
IL263463A (en) 2019-01-31
CR20180564A (es) 2019-03-04
FR3052452B1 (fr) 2018-06-22
PH12018502515A1 (en) 2019-09-30
CL2018003474A1 (es) 2019-05-24
HRP20200361T1 (hr) 2020-06-12
KR20190016106A (ko) 2019-02-15
GEP20207160B (en) 2020-10-12
MX374794B (es) 2025-03-06
RU2743163C2 (ru) 2021-02-15
CA3027014A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
JP6928005B2 (ja) 新規なピペリジニル誘導体、それらの調製方法及びそれらを含有する医薬組成物
US11667635B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
US10851105B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
CA3083320C (en) Piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
HK40004049A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40007201B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40007201A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
OA19084A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK40034164A (en) New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
EA051246B1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
NZ713074A (en) Bicyclic heterocycles as fgfr inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004049

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40004049

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210914

CF01 Termination of patent right due to non-payment of annual fee